Sreekanth Reddy

418 total citations
11 papers, 289 citations indexed

About

Sreekanth Reddy is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Sreekanth Reddy has authored 11 papers receiving a total of 289 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 3 papers in Molecular Biology. Recurrent topics in Sreekanth Reddy's work include Lung Cancer Treatments and Mutations (4 papers), Lung Cancer Diagnosis and Treatment (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Sreekanth Reddy is often cited by papers focused on Lung Cancer Treatments and Mutations (4 papers), Lung Cancer Diagnosis and Treatment (3 papers) and Cancer Immunotherapy and Biomarkers (3 papers). Sreekanth Reddy collaborates with scholars based in United States, Canada and Spain. Sreekanth Reddy's co-authors include Otis W. Brawley, Michael Benjamin, Marc A. Shapiro, G. Ramkumar, Jessica A. Sorrentino, Shannon R. Morris, Iveta Kudaba, Yili Pritchett, Davey B. Daniel and Amiran Matitashvili and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

In The Last Decade

Sreekanth Reddy

10 papers receiving 280 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sreekanth Reddy United States 6 178 96 72 47 32 11 289
Annelieke E.C.A.B. Willemsen Netherlands 10 145 0.8× 102 1.1× 89 1.2× 33 0.7× 31 1.0× 25 298
Jacqueline Wang United States 9 125 0.7× 46 0.5× 81 1.1× 42 0.9× 18 0.6× 20 279
Qingyu Wang China 10 127 0.7× 76 0.8× 47 0.7× 29 0.6× 32 1.0× 48 264
Meagan S. Barbee United States 6 232 1.3× 91 0.9× 71 1.0× 25 0.5× 22 0.7× 8 331
Gary Zeger United States 12 156 0.9× 151 1.6× 61 0.8× 43 0.9× 16 0.5× 19 315
A Pedrazzini Switzerland 10 134 0.8× 69 0.7× 44 0.6× 66 1.4× 22 0.7× 23 245
Pierre‐Marie Morice France 7 243 1.4× 39 0.4× 97 1.3× 35 0.7× 13 0.4× 21 382
Tristan Maurina France 10 108 0.6× 154 1.6× 118 1.6× 17 0.4× 24 0.8× 30 293
Damé Idossa United States 7 107 0.6× 77 0.8× 52 0.7× 73 1.6× 14 0.4× 22 256
Guilherme Harada Brazil 11 155 0.9× 161 1.7× 90 1.3× 19 0.4× 17 0.5× 40 317

Countries citing papers authored by Sreekanth Reddy

Since Specialization
Citations

This map shows the geographic impact of Sreekanth Reddy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sreekanth Reddy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sreekanth Reddy more than expected).

Fields of papers citing papers by Sreekanth Reddy

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sreekanth Reddy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sreekanth Reddy. The network helps show where Sreekanth Reddy may publish in the future.

Co-authorship network of co-authors of Sreekanth Reddy

This figure shows the co-authorship network connecting the top 25 collaborators of Sreekanth Reddy. A scholar is included among the top collaborators of Sreekanth Reddy based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sreekanth Reddy. Sreekanth Reddy is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Reddy, Sreekanth & G. Ramkumar. (2022). Novel Technique for Segmentation and Identification of Diabetic Retinopathy in Retinal Images Using GMM and Compare Accuracy with SVM. ECS Transactions. 107(1). 13773–13784. 9 indexed citations
2.
Leighl, Natasha B., Mary W. Redman, Naiyer A. Rizvi, et al.. (2021). Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760). Journal for ImmunoTherapy of Cancer. 9(8). e002973–e002973. 38 indexed citations
3.
4.
Daniel, Davey B., Vladimer Kuchava, Igor Bondarenko, et al.. (2020). Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive‐stage small cell lung cancer: A multicentre, randomised, double‐blind, placebo‐controlled Phase II trial. International Journal of Cancer. 148(10). 2557–2570. 59 indexed citations
5.
Mazières, Julien, Dariusz M. Kowalski, Alexander Luft, et al.. (2019). Health-Related Quality of Life With Carboplatin-Paclitaxel or nab-Paclitaxel With or Without Pembrolizumab in Patients With Metastatic Squamous Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 38(3). 271–280. 57 indexed citations
6.
Mazières, Julien, Dariusz M. Kowalski, Alexander Luft, et al.. (2018). Health-related quality of life (HRQoL) for pembrolizumab or placebo plus carboplatin and paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC: Data from KEYNOTE-407. Annals of Oncology. 29. viii748–viii749. 2 indexed citations
7.
Reddy, Sreekanth, et al.. (2016). Abstract 339: Identification of novel covalent inhibitors of K-Ras G12C that are efficacious in a xenograft model of NSCLC. Cancer Research. 76(14_Supplement). 339–339. 1 indexed citations
8.
Spetzler, David, Nanjie Xiao, K. Burnett, et al.. (2015). 254 Multi-platform molecular profiling of 1,180 patients increases median overall survival and influences treatment decision in 53% of cases. European Journal of Cancer. 51. S44–S44. 1 indexed citations
9.
Reddy, Sreekanth, et al.. (2003). Prostate cancer in black and white Americans. Cancer and Metastasis Reviews. 22(1). 83–86. 50 indexed citations
10.
Benjamin, Michael, Sreekanth Reddy, & Otis W. Brawley. (2003). Myeloma and race: A review of the literature. Cancer and Metastasis Reviews. 22(1). 87–93. 69 indexed citations
11.
Bonomi, Philip, L. Penfield Faber, Sreekanth Reddy, et al.. (1994). Prognostic significance of histologic complete remission in neoadjuvant trials in stage III non-small cell lung cancer (NSCLC). Lung Cancer. 11. 181–181. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Annelieke E.C.A.B. Willemsen Breakdown of academic impact, for papers by Jacqueline Wang Breakdown of academic impact, for papers by Qingyu Wang Breakdown of academic impact, for papers by Meagan S. Barbee Breakdown of academic impact, for papers by Gary Zeger Breakdown of academic impact, for papers by A Pedrazzini Breakdown of academic impact, for papers by Pierre‐Marie Morice Breakdown of academic impact, for papers by Tristan Maurina Breakdown of academic impact, for papers by Damé Idossa Breakdown of academic impact, for papers by Guilherme Harada
Rankless by CCL
2026